Antares Pharma, Ipl, AG
Records under this name other than patents Antares Pharma, Ipl, AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Antares Pharma, Ipl, AG
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,980,309 | Transdermal Testosterone Formulation for Minimizing Skin Residues Term ended Term ended May 2, 2026 · Medium confidence | Term ended | Term ended May 2, 2026 | Medium confidence |
| US 8,647,665 | Methods of treating hot flashes with formulations for transdermal or transmucosal application Lapsed on the fee record Ended Feb 11, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 11, 2026 | USPTO record |
| US 9,682,087 | Nestorone®/estradiol transdermal gel Formerly held Lapsed on the fee record Ended Jun 20, 2025 · USPTO record | Lapsed on the fee record | Ended Jun 20, 2025 | USPTO record |
| US 7,335,379 | Transdermal Pharmaceutical Formulation for Minimizing Skin Residues Term ended Ended no later than Oct 6, 2024 · Medium confidence | Term ended | Ended no later than Oct 6, 2024 | Medium confidence |
| US 8,268,346 | Methods of treating hot flashes with formulations for transdermal or transmucosal application Lapsed on the fee record Ended Sep 18, 2024 · USPTO record | Lapsed on the fee record | Ended Sep 18, 2024 | USPTO record |
| US 8,980,290 | Transdermal compositions for anticholinergic agents Term ended Term ended Aug 12, 2022 · USPTO record | Term ended | Term ended Aug 12, 2022 | USPTO record |
| US 7,198,801 | Formulations for Transdermal or Transmucosal Application Term ended Ended no later than Jun 25, 2022 · Medium confidence | Term ended | Ended no later than Jun 25, 2022 | Medium confidence |
| US 7,470,433 | Formulations for Transdermal or Transmucosal Application Term ended Ended no later than Aug 3, 2021 · Medium confidence | Term ended | Ended no later than Aug 3, 2021 | Medium confidence |
| US 8,652,491 | Transdermal compositions for anticholinergic agents Term ended Ended no later than Aug 3, 2021 · USPTO record | Term ended | Ended no later than Aug 3, 2021 | USPTO record |
| US 8,338,400 | Methods and apparatus for transdermal or transmucosal application of testosterone Lapsed on the fee record Ended Dec 25, 2020 · USPTO record | Lapsed on the fee record | Ended Dec 25, 2020 | USPTO record |